



Contraception is known to directly contribute to a reduction in 
maternal mortality rates. This is because a lot of pregnancies 
which ended in maternal mortality were unwanted. Thus, 
the prevention of unwanted pregnancies would lead to the 
prevention of maternal mortality related to them.[1,2]
Nigeria did not meet the Millennium Development 
Goals (MDGs) in general and MDG-5 in particular which 
was aimed at improvement of maternal health (with its 
accompanying targets).[3,4] We need to make concerted efforts to 
meet the Sustainable Development Goals (SDGs 2015–2030) 
in general and Goal 3 in particular (Good health and well-being 
for people), which is directly related to maternal and child 
health.[5]
Jadelle is a long-acting, reversible modern method of 
contraception. It was developed by the Population Council 
in the 1980s. It was subjected to multicenter trials in seven 
countries from 1990. The outcome of these trials assured the 
safety and efficacy of Jadelle before it was approved for use 
in Europe, America, and parts of Asia.[6,7]
Jadelle is a hormonal implant which consists of two thin, 
cylindrical, flexible silicon rods (2.5 mm in diameter and 
4.3 mm in length) each containing 75 mg levonorgestrel. It is a 
safe, affordable, highly effective, and convenient contraceptive 
method, currently labeled for 5 years of use.[8-13]
Each rod of Jadelle releases about 100 μg/day of levonorgestrel 
in the 1st month of insertion. This reduces to about 40 μg/
day within 1 year after insertion. This reduces further to 
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about 30 μg/day within 3 years of insertion and then to about 
25 μg/day by the end of the 5th year after insertion.[8,12,13]
The annual pregnancy rate per 100 users of Jadelle is 0.1 for 
the first 3 years, 0.4 in the 4th year, and 0.85 at the end of the 
5th year of use. The Pearl index by the end of the 5th year of 
use is 0.17/100 women-years.
The contraceptive effect of Jadelle works by three major 
mechanisms of action which are ovulation suppression, 
thickening of cervical mucus, and induction of endometrial 
atrophy.[8,12,13]
The common side effects of Jadelle include irregular menstrual 
bleeding (heavy/light or frequent/infrequent), amenorrhea, 
application site reactions, headache, dizziness, breast pain, 
premenstrual syndrome, weight gain, urinary tract infection, 
pelvic pain, and anxiety.
Contraindications to the use of Jadelle include undiagnosed 
abnormal vaginal bleeding, breast tumors, benign/malignant 
liver disease, endometrial cancer, thrombosis/thromboembolic 
disorder, allergy to levonorgestrel, or other components of 
Jadelle implant.[8-15]
It is a provider-dependent method for both insertion and 
removal. It is usually inserted by a minor surgical procedure 
subdermally into the medial aspect of the nondominant arm. 
Removal also needs a minor surgery which may take a longer 
period than its insertion and may be more painful. Jadelle 
can be removed at any time of the menstrual cycle but must 
not be retained beyond 5 years after its insertion. Once the 
implants are removed, there is an almost immediate return of 
fertility.[12,13]
Jadelle was introduced into the family planning unit of the 
University of Calabar Teaching Hospital (UCTH) in 2005. 
Before then, our facility had previous experience with another 
implant (Norplant) which was withdrawn in 2005 shortly 
before the introduction of Jadelle. After insertion of Jadelle, the 
first follow‑up visit is after 6 weeks and the second follow‑up 
visit after 6 months. Thereafter, yearly follow-up visits are 
scheduled. During follow-up visits, the clients’ weights and 
blood pressure are checked. They are also asked about the 
presence of side effects.
The clients are encouraged to present in the clinic at any time 
that they may develop side effects and not to wait for scheduled 
follow-up visits. Whenever pregnancy is suspected, a blood 
pregnancy test is carried out for confirmation.
The objective of this study were to determine the 
sociodemographic profile of Jadelle users, side effects and 
reasons for discontinuation of the product at the UCTH, 
Calabar, Nigeria.
Methodology
This was a 5-year retrospective study carried out in the family 
planning clinic of the UCTH, Calabar, between January 1, 
2013, and December 31, 2017. Case files of women who 
accepted and inserted Jadelle implant were retrieved, and 
data were extracted for the study. Data collected included 
the sociodemographic profile, reproductive history, previous 
method of contraception used, side effect profile, and reasons 
for discontinuation. The contraceptive efficacy of Jadelle was 
determined by the number of confirmed pregnancies which 
occurred during the period of the study.
Statistical analysis
Data were entered into Excel, descriptive and analytical 
statistics of the data using mean and standard deviation were 
done, and results were presented in frequency and percentage 
tables.
results
During the study period, 270 clients accepted and inserted a 
Jadelle implant as a method of contraception at the UCTH, 
Calabar, Nigeria.
The sociodemographic profile of these Jadelle users, as shown 
in Table 1, revealed that a majority (65.6%) of them belong 
to the age group of 30–39 years, 54 (20%) and 31 (11.5%) 
were 20–29 years and 40–49 years, respectively, and only 
7 (2.6%) were teenagers.[10-19] The mean age of Jadelle users 
was 33.0 ± 6.2.
A vast majority (98.1%) were Christians, whereas 1.9% were 
Muslims. The majority (63.3%) of the Jadelle users (171, 
63.3%) had tertiary level education, 63 (23.4%) and 34 (12.6%) 
had secondary and primary school education, respectively, 
whereas only 2 (0.7%) had no formal education.
The number of live children of the Jadelle users (10, 3.7%) 
had no children, 34 (12.6%) had 1 or 2, 171 (63.3%) had 3 or 
4, whereas 55 (20.1%) had five or more living children.
The proportion of Jadelle users who still had a desire to 
have more children in the future was 134 (49.6%), whereas 
128 (47.4%) had no desire to have more children and 8 (3.0%) 
were uncertain, as shown in Figure 1.
Out of the 270 users, 104 (38.5%) had never used any other 
method of contraception. Those who have previously used 
implants were 52 (19.2%), injectables 38 (14.1%), Intra 
uterine contraceptive device (IUCD) 24 (8.9%), whereas pills, 
condoms, and natural methods were 19 (7.0%), 22 (8.1%), and 
11 (4.1%), respectively [Table 2].
During the study period, 131 (48.5%) Jadelle users reported 
side effects, whereas 43 (15.9%) reported no side effect. 
The most commonly reported side effect was menstrual 
irregularities (55.0%), followed by amenorrhea (24.4%) 
and 5 (3.8%) weight gain, whereas 22 (16.8%) had other 
side effects such as dizziness, skin changes, increased blood 
pressure, and abdominal bloating. However, 96 (35.6%) 
attended no follow-up visit after insertion of Jadelle, as shown 
in Figures 2 and 3.
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Table 1: Sociodemographic profile of Jadelle implant 
acceptors






















Figure 4 shows that 37 (13.7%) Jadelle users had their implants 
removed and discontinued usage during the study period.
The reasons for discontinuation were menstrual irregularities in 
16 (43.3%), desire to get pregnant in 6 (16.2%), and excessive 
weight gain 5 (13.5%). Amenorrhea and expiration of the 
implant were also reasons for discontinuation in 4 (10.8%) 
each, whereas other reasons such as raised blood pressure and 
skin changes were the reasons in 2 (5.4%) of them.
dIscussIon
The sociodemographic profile of these clients showed that 
majority (65.6%) of the Jadelle acceptors were aged between 
30 and 39 years and the mean age was 33.0 ± 6.2.
This is similar to studies done in Jos,[15] Port Harcourt,[9] 
Ogbomoso,[16] and Zaria.[17] Contrary to this, only seven teenagers 
were involved, which accounted for 2.6% of the clients. This is 
higher than the 0.4% of teenagers reported in a similar study in 
Jos[15] but lower than 7.5% reported in another study in Zaria.[17]
The Nigerian adolescents’ use of family planning clinics is 
poor and even worse still is their use of long-acting reversible 
contraceptives (LARCs). This is because the family planning 
clinics are not adolescent-friendly and are thus used almost 
exclusively by married women.[18,19] However, the situation 
is different in many parts of America and Europe, where 
adolescents significantly use family planning clinics and 
LARCs such as implants.[20-22]
Among the Jadelle acceptors during the study period, 63.3% 
had tertiary education and 22.6% had secondary education; 
thus, 85.9% of the clients had at least secondary education or 
more. Christians were 98.1%, whereas 1.9% were Muslims. 
Both the above statistics are higher than the 73%, and 88.8% 
reported, respectively, from a similar study in Jos, Nigeria.[15] 
This study was based in the southern part of the country 
where there are predominantly Christians. However, it is 


































Figure 2: Proportion of Jadelle users with side effects to those without 
side effects
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known from previous studies that education and religion are 
strong predictors of the acceptance of modern methods of 
family planning. It was found that women, who had tertiary 
education, were more likely to accept modern family planning 
methods than the others. The Christians were also found to be 
more likely to accept modern family planning methods than 
the Muslims.[23-25]
Despite the fact that almost half (49.7%) of the clients had 4 
children or more before using Jadelle implant [Table 1], almost 
half (49.6%) still had the desire to have more children in the 
future [Figure 1]. This is in agreement with the high total 
fertility rate in Nigeria, which is put at 5.7.[19,26]
Although the contraceptive prevalence rate in Nigeria is 
generally low,[18,19] our study shows that majority (61.5%) 
of our clients had previously used at least one method of 
contraception, with implants (19.2%) being the predominant 
method, followed by injectables (14.1%), IUCD (8.9%), and 
condom (8.1%).
This is different from a similar study in Jos, where 82% had 
previously used a modern method of contraception. These used 
predominantly the short-acting methods being injectables, oral 
contraceptive pills, and condom.[15]
During the study period, 37 (13.7%) discontinued Jadelle 
use. The most common reason for discontinuation (43.3%) 
was menstrual irregularities, which was not surprising 
since menstrual irregularit ies were also the most 
common (55.0%) reported side effect. Although these 
complaints are usually not life-threatening, they make 
life uncomfortable for these women, affecting their social 
and sexual lives. In addition, it is the added cost of buying 
sanitary pads frequently. However, this is different from 
a similar study in Jos, where the most common reason 
for discontinuation was the desire for more children.[15] 
This is also different from studies in both Zaria[17] and 
Port Harcourt,[9] where the most common reason for 
discontinuation was the expiration of the method.
The fact that only 37 (13.7%) discontinued the method 
whereas 131 (48.5%) had side effects supports the fact 
that complications do not always lead to discontinuation, 
especially when good counseling had been given preinsertion. 
This may also be due to the fact that the relatively most 
common side effect, being menstrual irregularities, usually 
remits within 6 months or with the use of medications.[27,28] 
Moreover, the most common side effects are experienced in 
all progestogen-only contraceptives.[29,30]
During the study period, 96 (35.6%) of the clients did not 
return for any follow‑up visit. There was no way of confirming 
whether these clients had side effects/discontinued the method 
or not. This is a constraint of this study.
Only one woman was confirmed pregnant during the study 
period after 1 year 7 months of using Jadelle implant. This was 
a true failure as a pregnancy occurred remote from insertion 
and was confirmed by a blood pregnancy test. The Pearl index 
was 0.074, which shows high contraceptive effectiveness.
conclusIon
Jadelle is a highly effective, safe, and reversible method 
of contraception. The most commonly reported side effect 
was menstrual irregularities, which was also the most 
common reason for discontinuation in the UCTH, Calabar, 
Nigeria. We recommend intensifying counseling and 
follow-up process by collecting clients’ phone numbers 
and ensuring correct residential addresses during insertion. 
These measures will improve the return for follow-up and 
enable clients to be reached out to when the due follow-up 
period elapses.
Good preinsertion counseling and follow-up of the clients 
postinsertion will help in meeting the contraceptive needs 
of these women, which will ultimately help in reducing the 
maternal mortality ratio.
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IUCD: Intra uterine contraceptive device
































































Figure 4: Reasons for discontinuation by Jadelle users
Odusolu and Eyong: Uptake and discontinuation of Jadelle implant use
references
1. Canning D, Schultz TP. The economic consequences of reproductive 
health and family planning. Lancet 2012;380:165-71.
2. Schultz TP, Shareen J. Family planning and women’s and children’s 
health: Consequences of an outreach program in Matlab, Bangladesh. 
Demography 2013;50:149-80.
3. CEPAL – MDG Goals, Targets and Indicators. Available from: https://
www.cepal.org>ci-bin>getprod. [Last accessed on 2019 Jan 15].
4. Oleribe OO, Taylor-Robinson SD. Before sustainable development 
goals (SDG): Why Nigeria failed to achieve the millennium development 
goals (MDG). Pan Afr Med J 2016;24:156.
5. Sustainable Development Goals. Available from: https://
sustainabledevelopment.un.org>sdg. [Last accessed on 2019 Jan 15].
6. Laphikanont W, Taneepanichskul S. Effects of Jadelle used in Thai 
women aged between 20 and 45 years in King Chulalongkorn Memorial 
Hospital. J Med Assoc Thai 2006;89:761-6.
7. Ramchandran D. Upadhyay U. D. Implants. The Next Generation 
Report Series, No. 7. Baltimore: Info Project John Hopkins Bloomberg 
School of Public Health; 2007.
8. Inyang‑Etoh EC, Akpan AS. Side effect profile of Jadelle implant 
in Nigerian women during the first 12 months of usage. Int J Reprod 
Contracept Obstet Gynecol 2016;5:1461-6.
9. Oranu EO, Ojule JD. A decade of Jadelle subdermal implant in a 
tertiary health institution in Port Harcourt, Southern Nigeria. JBM 
2018;6:123-30.
10. Abasiattai AM, Utuk NM, Inyang-Etoh EC. Subdermal contraceptive 
implants: Profile of acceptors in a tertiary hospital in Southern Nigeria. 
Int J Gynaecol Obstet Neonatal Care 2014;1:9-13.
11. Eke AC, Alabi-Isama L. Long-acting reversible contraception (LARC) 
use among adolescent females in secondary institutions in Nnewi, 
Nigeria. J Obstet Gynaecol 2011;31:164-8.
12. Bayer New Zealand Limited. Jadelle Medsafe Medicare Safety Data 
Sheet. Available from: http://www.medsafe.govt.nz. [Last accessed on 
2010 Sep].
13. Sivin I, Nah H, Waldman S. Jadelle Levonorgestrel Rod Implants: 
A Summary of Scientific Data and Lessons Learnt from Programmatic 
Experiences. New York: Production Council; 2002. Available from: 
http://www.popcouncil.ord/pdfs/Jadelle-monograph.pdf. [Last accessed 
on 2010 Sep].
14. Casey PM, Long ME, Marnach MI, Bury JE. Bleeding related to 
etonogestrel Subdermal implant in a U.S. population. Contraception 
2011;83:426-30.
15. Pam VC, Mutihir JT, Nyango DD, Shambe J, Egbodo CO, Karshima JA. 
Sociodemographic profiles and use‑dynamics of Jadelle (Levonorgestrel) 
implants in Jos, Nigeria. NMJ 2016;57:314-18.
16. Adeyemi AS, Owonikoko KM, Adekanle DA, Aworinde O. Subdermal 
contraceptive implants: Experience at a tertiary health institution in 
South-Western Nigeria. Sahel Med J 2018;21:137-40.
17. Madugu NH, Abdu MA, Bawa U, Kalawole B. Uptake of hormonal 
implant contraceptives in Zaria, Northern Nigeria. Open J Obstet 
Gynaecol 2015;5:268-73.
18. Abiodun OM, Balogun OR. Sexual activity and contraceptive use 
among young female students of tertiary educational institutions in 
Ilorin, Nigeria. Contraception 2009;79:146-9.
19. Monjok E, Smesny A, Ekabua JE. Contraceptive practices in Nigeria: 
Literature review and recommendation for future policy decisions. Open 
Access Contraception 2009;79:146-9.
20. Guazzelli CA, de Queiroz FT, Barbieri M, Torloni MR, de Araujo FF. 
Etonogestrel implant in adolescents: Evaluation of clinical aspects. 
Contraception 2011;83:336-9.
21. Mestad R, Secura G, Allsworth JE, Madden T, Zhao Q, Peipert JF. 
Acceptance of long-acting reversible contraceptive methods by 
adolescent participants in the contraceptive CHOICE project. 
Contraception 2011;84:493-8.
22. Lewis LN, Doherty DA, Hickey M, Skinner SR. Implanon as a 
contraceptive choice for teenage mothers: A comparison of contraceptive 
choices, acceptability and repeat pregnancy. Contraception 2010;81:421-6.
23. Ankomah A, Anyanti J, Oladosu M. Myths, misinformation and 
communication about family planning and contraceptive use in Nigeria. 
Open Assess J Contracept 2011;2:95-105.
24. Palamuleni ME. Socio‑economic and demographic factors affecting 
contraceptive use in Malawi. Afr J Reprod Health 2013;17:91-104.
25. Marrone G, Abdul-Rahman L, De Coninck Z, Johansson A. Predictors 
of contraceptive use among female adolescents in Ghana. Afr J Reprod 
Health 2014;18:102-9.
26. National Population Commission (NPC) and ICF Macro. Nigeria 
Demographic Health Survey 2008: Key Findings. Vol. 11. Calverton, 
Maryland, USA: NPC and ICF Macro; 2009. p. 63-86.
27. Friedlander E. Therapeutic options to unscheduled vaginal bleeding 
associated with long-acting reversible contraception. Obstetr Gynaecol 
Clin North Am 2015;42:593-603.
28. Hou MM, McNicholas C, Creinin MD. Combined oral contraceptive 
treatment for bleeding complaints with etornorgestrel contraceptive 
implant: A randomized control trial. Eur J Contracept Reprod Healthc 
2016;21:361-6.
29. Akadri AA, Odelola OI. Progestogen – Only injectible contraceptive: 
Acceptor prevalence and client experience at Sagamu, Nigeria. Niger 
Postgrad Med J 2017;24:178-81.
30. Adeyemi AS, Adekanle DA. Progestogen-only injectable contraceptive: 
Experience of women in Osogbo, Southwestern Nigeria. Ann Afr Med 
2012;11:27-31.
Nigerian Journal of Medicine ¦ Volume 29 ¦ Issue 2 ¦ April-June 2020290
